- Home
- JLL vs VTRS Comparison
JLL vs VTRS Comparison
Compare JLL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- VTRS
- Stock Information
- Founded
- JLL 1997
- VTRS 1961
- Country
- JLL United States
- VTRS United States
- Employees
- JLL N/A
- VTRS N/A
- Industry
- JLL Real Estate
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- JLL Finance
- VTRS Health Care
- Exchange
- JLL Nasdaq
- VTRS Nasdaq
- Market Cap
- JLL 14.5B
- VTRS 11.8B
- IPO Year
- JLL 1997
- VTRS N/A
- Fundamental
- Price
- JLL $313.63
- VTRS $9.60
- Analyst Decision
- JLL Buy
- VTRS Hold
- Analyst Count
- JLL 8
- VTRS 5
- Target Price
- JLL $328.57
- VTRS $10.40
- AVG Volume (30 Days)
- JLL 403.1K
- VTRS 8.3M
- Earning Date
- JLL 11-05-2025
- VTRS 11-06-2025
- Dividend Yield
- JLL N/A
- VTRS 5.00%
- EPS Growth
- JLL 47.74
- VTRS N/A
- EPS
- JLL 11.64
- VTRS N/A
- Revenue
- JLL $24,676,200,000.00
- VTRS $14,115,700,000.00
- Revenue This Year
- JLL $12.26
- VTRS N/A
- Revenue Next Year
- JLL $8.77
- VTRS $1.66
- P/E Ratio
- JLL $26.92
- VTRS N/A
- Revenue Growth
- JLL 13.47
- VTRS N/A
- 52 Week Low
- JLL $194.36
- VTRS $6.85
- 52 Week High
- JLL $316.79
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- JLL 67.75
- VTRS 34.63
- Support Level
- JLL $305.81
- VTRS $10.33
- Resistance Level
- JLL $316.79
- VTRS $10.55
- Average True Range (ATR)
- JLL 5.85
- VTRS 0.22
- MACD
- JLL -0.61
- VTRS -0.14
- Stochastic Oscillator
- JLL 85.36
- VTRS 1.94
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.